Services offered by EATRIS include

• support funding applications (Identification of partners for consortium building, assessment of the project plan's impact and innovation potential)
• translational research facilities and expertise for development of novel biomarkers, diagnostics and therapeutics
• molecular, functional & hybrid imaging technologies, preclinical models, samples, patient cohorts, GMP manufacturing
• regulatory and Health Technology Assessment (HTA) expertise
• advice on intellectual property issues and industry partnering strategy (innovation management)

Costs are calculated on a case by case basis depending on the service required; some services can also be provided as part of funding proposals with EATRIS joining consortia as partner or subcontractor.
For further information please contact us.

Services performed can be offered either centrally by the coordination and support team based in Amsterdam or remotely by the EATRIS institutions.

Translating novel biology insights into effective interventions or medical applications is a highly complex process. It requires significant dedicated expertise, facilities and resources. We believe in your medical innovation and we want to support you by bringing together the multi-disciplinary expertise and infrastructure required for optimising your translational trajectory. Working with EATRIS gives greater confidence in the translational feasibility of your project and its impact.

In cooperation with EPPN2020, EMPHASIS offers access to plant phenotyping infrastructures, which includes

• high-throughput facilities
• lean field facilities
• intensive field facilities
• assay development
• data management

Further services are currently under development and will be implemented in its operational phase.

The access provided currently via EPPN2020 is free of charge for selected user-groups, based on a simple application procedure and includes the logistical, technological and scientific support as well as specific training required to successfully complete the approved Transnational Access project.
For further information please contact us.

European-wide access to plant phenotyping infrastructures is currently under development in our partner project EPPN2020 and is provided via its homepage.

Access will be accordingly provided by EMPHASIS once it reaches its operational phase.

EPPN2020 provides transnational access to plant phenotyping infrastructure as a basis for novel scientific approaches to quantitative plant assessment in high throughput. The installations represent a diverse set of facilities for plant phenotyping in Europe with focus on: i) non-invasive high-throughput phenotyping under controlled conditions, ii) destructive sampling aiming at assessing underlying traits helping to understand the genetic variability of different plant processes, iii) controlled field facilities allowing users to control rainfall and/or the concentration of air CO2 together with high-definition, non-invasive sensors. Transnational access will be available based on a simple and transparent access procedure.

Services provided by EU-OPENSCREEN include

• high-throughput compound/ drug screening (HTS): HTS of an assay against the EU-OPENSCREEN chemical collection (> 100,000 compounds); in silico profiling; hit selection; confirmatory screening; basic counter screening; basic SAR based on screening data; QC of confirmed hits

• access to a unique European compound collection: EU-OPENSCREEN chemical collection (> 100,000 compounds)

• assay adaption: This assay adaptation process will involve a strong emphasis on quality, including: quality control of reagents; (patho-)physiological relevance; pharmacological consistency; robustness; minimised variability; and tracking of statistical descriptors (e.g. signal to background and the Z’ factor) 

• chemical optimization and profiling of preliminary ‘hits’

• bioprofiling of donated compounds: All compounds donated by the user which enter the EU-OPENSCREEN ERIC compound collection are characterised and annotated for basic physico-chemical (e.g. identity, solubility, light absorbance and fluorescence) and essential to know biological properties (cytotoxicity, antibiotic, antifungal etc.) by testing in a standard panel of assays.

• provision of standardised data: All data generated through QC/bioprofiling and screening activities will be published in EU-OPENSCREEN’s open-access database with an optional ‘grace’ period (i.e. delayed publication of data). Large-scale open-access data provide the basis for computational data integration to obtain a systematic view, allow for prediction of drug-target interactions and networks as well as of adverse effects and drug combinations. The access to the EU-OPENSCREEN database will utilize the facilities of ChEMBL.

• training and education activities

A screening project at a typical EU-OPENSCREEN screening site will cost 50-250k €, strongly depending on the number of screened substances and the maturity/ complexity of the assay.
A compound replenishment fee structure applies to all projects using the EU-OPENSCREEN compound collection and users from countries which are members of the EU-OPENSCREEN ERIC will receive a discount on this cost.
For further information please contact us.

Users are requested to submit project proposal to the EU-OPENSCREEN office. Depending on the project requirements, the RI can be assessed remotely or on-site.

The majority of scientists in Europe do not have access to suitable technology platforms and compound collections, which are generally expensive to purchase, operate and maintain. As a large-scale research infrastructure (RI) with an ‘open’ pre-competitive character, EU-OPENSCREEN will cost-effectively overcome this limitation by: involving and providing access to Europe’s leading screening platforms and chemistry groups; offering a jointly used rationally designed compound collection; and operating an open-access bioactivity database which will be accessible on a global basis. EU-OPENSCREEN offers to support you through grant application processes and beyond for funding involving screening projects.

Services offered by Instruct include

• Sample Preparation: Crystallisation, Nanobody Discovery, Protein Production;
• Biomolecular Analysis: Imaging, Mass Spectrometry, Molecular Biophysics;
• 3D Structural Analysis: Electron Microscopy, Magnetic Resonance Techniques, X-ray Techniques;
• Compuational Services for Structural Biology: Bioinformatics Tools, Integrative Modelling, Crystallography, Electron Microscopy, NMR

https://instruct-eric.org/platform-catalogue

Free for academic users; on service-basis for commercial use (user access is on a fee for service basis; no obligation to disclose or publish data).
Users can apply for travel and accommodation costs where a physical visit to an Instruct facility is required.
For further information please contact us.

Depending on the requested service, access can be on-site, remote, or mail-in sample.

For further information please contact us.

Instruct is at the cutting edge of new technologies: automation, remote access, new detector methods, advanced imaging. Access to Instruct-ERIC infrastructure can help advance your research - more than 1200 peer-reviewed scientific publications acknowledge Instruct.

MIRRI services comprise

• access to microorganisms/cell lines deposited in public collections
• deposit of microorganisms/cell lines (public collection/patents)
• phenotypic/molecular characterisation of microorganisms
• identification/molecular typing of microorganisms
• isolation/cultivation/preservation of microorganisms
• microbial community analyses
• microbial phylogenetic studies
• screening/bioassays with microorganisms
• access to microbiological databases
• consultancy/contract research
• legal issues (e.g. Nagoya Protocol)
• biosafety/biosecurity
• training

Costs depend on the kind of service requested.
For further information please contact us.

Access modes depend on the kind of service requested.
For further information please contact us.

MIRRI offers not only a broad spectrum of high quality microorganisms, but also a longlasting expertise in each field of microbiology. Aiming at harmonising the current microbial Biological Resource Centre (mBRC) landscape, MIRRI enables facilitated access to deposited microorganisms and is constantly improving the corresponding state-of-the-art service offers. Our experts ensure legal compliance of resources (Nagoya Protocol) and with the envisaged interoperability of existing and future databases researchers can exploit the full value of microorganisms.